N-acetylcysteine for the treatment of COVID-19 among hospitalized patients


      • Low serum levels of H2S in COVID-19 pneumonia are associated with a poor prognosis.
      • Endogenous H2S production can be increased therapeutically by administering NAC.
      • NAC therapy was associated with improvement in SpO2/FiO2, CRP, and NEWS2 scale.
      • There were no significant differences in the clinical outcomes (IMV, mortality).
      • NAC therapy was not associated with moderate and severe adverse events.


      To read this article in full you will need to make a payment


      Subscribe to Journal of Infection
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Horby P.
        • Lim W.S.
        • Emberson J.R.
        • Mafham M.
        • Bell J.L.
        • Linsell L.
        • et al.
        • RECOVERY Collaborative Group
        Dexamethasone in hospitalized patients with COVID-19.
        N Engl J Med. 2021; 384: 693-704https://doi.org/10.1056/NEJMoa2021436
        • RECOVERY Collaborative Group
        Tocilizumab in patients admitted to hospital with COVID-19 (recovery): a randomised, controlled, open-label, platform trial.
        Lancet. 2021; 397: 1637-1645https://doi.org/10.1016/S0140-6736(21)00676-0
        • Hasan M.J.
        • Rabbani R.
        • Anam A.M.
        • Huq S.M.R.
        Secukinumab in severe COVID-19 pneumonia: does it have a clinical impact?.
        J Infect. 2021; 83: e11-e13https://doi.org/10.1016/j.jinf.2021.05.011
        • Bourgonje A.R.
        • Offringa A.K.
        • van Eijk L.E.
        • Abdulle A.E.
        • Hillebrands J.L.
        • van der Voort P.H.J.
        • et al.
        N-Acetylcysteine and hydrogen sulfide in Coronavirus disease 2019.
        Antioxid Redox Signal. 2021; https://doi.org/10.1089/ars.2020.8247
        • Renieris G.
        • Katrini K.
        • Damoulari C.
        • Akinosoglou K.
        • Psarrakis C.
        • Kyriakopoulou M.
        • et al.
        Serum hydrogen sulfide and outcome association in pneumonia by the SARS-CoV-2 coronavirus.
        Shock. 2020; 54: 633-637https://doi.org/10.1097/SHK.0000000000001562
        • Meyer A.
        • Buhl R.
        • Kampf S.
        • Magnussen H.
        Intravenous N-acetylcysteine and lung glutathione of patients with pulmonary fibrosis and normals.
        Am J Respir Crit Care Med. 1995; 152: 1055-1060https://doi.org/10.1164/ajrccm.152.3.7663783
        • Aldini G.
        • Altomare A.
        • Baron G.
        • Vistoli G.
        • Carini M.
        • Borsani L.
        • Sergio F.
        N-Acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why.
        Free Radic Res. 2018; 52: 751-762https://doi.org/10.1080/10715762.2018.1468564
        • Ibrahim H.
        • Perl A.
        • Smith D.
        • Lewis T.
        • Kon Z.
        • Goldenberg R.
        • et al.
        Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine.
        Clin Immunol. 2020; 219108544https://doi.org/10.1016/j.clim.2020.108544
        • Alamdari D.H.
        • Moghaddam A.B.
        • Amini S.
        • Keramati M.R.
        • Zarmehri A.M.
        • Alamdari A.H.
        • Damsaz M.
        • Banpour H.
        • Yarahmadi A.
        • Koliakos G.
        Application of methylene blue -vitamin C -N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial.
        Eur J Pharmacol. 2020; 885173494https://doi.org/10.1016/j.ejphar.2020.173494
        • de Alencar J.C.G.
        • Moreira C.L.
        • Müller A.D.
        • Chaves C.E.
        • Fukuhara M.A.
        • da Silva E.A.
        • et al.
        Double-blind, randomized, placebo-controlled trial with N-acetylcysteine for treatment of severe acute respiratory syndrome caused by COVID-19.
        Clin Infect Dis. 2021; 72: e736-e741https://doi.org/10.1093/cid/ciaa1443